Meta-analysisindependent cross-checkfull text checked★ key study I-SRC-109 in-depth review
Short fasting alongside cancer treatment
Dietary restriction during active cancer therapy is associated with improved treatment response: a systematic review and meta-analysis.
Overview
Agrawal K et al.. Cancer Biol Med 2026 · PMID 42444194 · DOI 10.20892/j.issn.2095-3941.2025.0841
In three small studies, patients who restricted food during chemotherapy had better tumour shrinkage on scans; survival was not studied.
Does the study support the specific claim? Partly · Methodological quality: low
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Pool studies of dietary restriction during cancer therapy
- How was the study done?
Systematic review and meta-analysis
- How many people, animals or samples were studied?
3 studies (169 patients) for response
- What was actually found?
Better radiological response; no clear change in toxicity or quality of life
- How large was the observed effect?
OR 4.55 (1.64-12.58), not reproducible (our MH 3.50)
- What do the results mean in everyday life?
Fasting is being studied only as an add-on to treatment
- What are the study's limitations?
Very small evidence base; reporting problems
- What does it say about Elawady's specific claim?
Does not support fasting instead of treatment
- Do the results apply to Germany and Europe?
Research setting
- What can explicitly not be concluded from this study?
Whether fasting prolongs life or replaces treatment
Scientific in-depth review
1. Full reference
- Authors
- Agrawal K et al.
- Journal
- Cancer Biol Med
- Year
- 2026
- Identifier
- PMID 42444194 DOI 10.20892/j.issn.2095-3941.2025.0841
- Verification
- verified – PubMed efetch 2026-10-26; Crossref works record checked
- Retracted
- no
- Corrections
- none
- Extent checked
- full text
- Conflicts of interest and funding
No conflicts disclosed; academic grants (Singapore).
2. Research question
Does dietary restriction (calorie restriction, fasting-mimicking diet, short-term fasting) during active cancer therapy improve treatment response?
3. Study design and population
- Study design
- Meta-analysis – Systematic review and meta-analysis (published as a letter); PROSPERO CRD42023460206
- Population
Patients with solid tumours during chemotherapy/radiotherapy; malnourished or cachectic patients generally excluded
- Country
International
- Period
Searches 1973 to October 2025
- Sample size
12 eligible studies stated (9 RCTs, 1 single-arm, 1 case report listed); response meta-analysis based on 3 studies (169 patients)
- Inclusion and exclusion criteria
Dietary restriction >=48 h during active cancer treatment
4. Methods and endpoints
- Exposure / intervention
Calorie restriction, FMD or short-term fasting as an adjunct
- Comparator
Usual diet during the same cancer therapy
- Endpoints
Radiological response (RECIST), toxicity, quality of life, metabolic markers
- Statistical methods
OR/SMD, random and fixed effects, I2
5. Actual results
- Results
Favourable treatment response: OR 4.55 (95% CI 1.64-12.58; random effects; I2 = 0%; 3 studies); fixed-effect OR 4.80 (1.74-13.25). Quality of life SMD 0.18 (-0.22 to 0.59; not significant). Toxicity: no significant pooled reduction. Insulin SMD -0.83 (-1.86 to 0.21; I2 88%), IGF-1 not significant (I2 92%). Survival not reported by included studies.
- Absolute risks
Not reported.
- Authors' conclusion
Dietary restriction during active cancer treatment was associated with favourable response without evidence of increased toxicity; adequately powered RCTs are needed; survival remains unexplored.
6. Strengths
- Pre-registered
- Focus on restriction as adjunct during therapy
- Full text read
7. Weaknesses
- Response analysis from only 3 small studies
- Our recalculation from the paper's Table 1 gives a Mantel-Haenszel OR of 3.50, not 4.80, and the pooled OR exceeds two of the three study ORs - the pooled figure could not be reproduced
- Study count inconsistent (12 stated, 11 described)
- Hormone-sensitive cancers predominate
- No survival outcomes
- Letter format
8. Risk of bias
- Orienting tool
- AMSTAR 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- high
- Rationale
Small evidence base, irreproducible pooled estimate, inconsistent reporting.
9. Assessment of the statistical interpretation
Per-study ORs from Table 1: Bahrami 3.75 (1.08-13.07), de Groot 2.89 (1.01-8.23), Riedinger 6.18 (0.26-146.8, continuity-corrected); recomputed MH OR 3.50 (stats/C-SRC-32_agrawal2026_or.py). Reported CIs are log-symmetric, so the discrepancy lies in the input data or method, not in arithmetic of the CI. Radiological response is a surrogate, not survival.
10. Relevance to the specific claim
The strongest supporting-side evidence: short, supervised dietary restriction as an add-on to chemotherapy may improve tumour response in selected, well-nourished patients. It does not test fasting instead of cancer treatment, nor survival.
11. Independent contrary findings
I-INTA-10 (no demonstrated effect on outcomes), I-SRC-108 (ESMO: adequate nutrition), I-CHM-03/04 (alternative-only care and mortality).
12. Transferability to Germany and Europe
Indirect; research setting only.
13. Overall methodological judgement
Hypothesis-generating; does not support fasting as a stand-alone cancer treatment.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | low |
| Risk of bias | high |
| Precision of results | low |
| Directness | indirect |
| Reproducibility | not replicated |
| Consistency with the overall evidence | unknown |
| Regional transferability | moderate |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Effect on survival; safety in malnourished patients; reproducibility of pooled estimate.